Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-09-20 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Q3 Share capital increase_EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'share capital increase arising from subscription right exercises,' detailing the number of new shares issued and the resulting total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2021-09-20 English
Q3 Share Capital Increase_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Galapagos NV dated September 20, 2021, announcing a capital increase resulting from the exercise of subscription rights. It details the number of new shares issued, the total capital raised (€151,787.50), and updates the total number of voting rights (the 'denominator') as required by Belgian transparency legislation regarding significant shareholdings. This content directly relates to changes in the company's capital structure and financing activities, specifically through the issuance of new shares following the exercise of rights. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate action related to capital.
2021-09-20 Dutch
6-K Filing
Regulatory Filings
2021-09-20 English
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Earnings Release Classification · 95% confidence The document is a press release dated September 17, 2021, announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Jyseleca® (filgotinib) for the treatment of ulcerative colitis. This type of announcement, detailing key clinical/regulatory milestones (like a positive opinion leading to expected final approval) and providing context on the drug and trial data, is characteristic of an Earnings Release (ER) or a general press release related to corporate/product updates. Since it is an initial announcement of a significant regulatory event (positive opinion) and not a comprehensive periodic report (like 10-K or IR), the most fitting category is Earnings Release (ER), which often encompasses major corporate news releases, especially those related to clinical/regulatory progress that impacts future earnings potential. It is not a transcript (CT), a full annual report (10-K), or a specific management/board change (MANG). It is a direct announcement of results/news, not just an announcement *about* a report (RPA). Q3 2021
2021-09-17 English
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Earnings Release Classification · 95% confidence The document is a press release dated September 17, 2021, announcing that the CHMP has issued a positive opinion for Jyseleca (filgotinib) for Ulcerative Colitis, noting that a final decision from the European Commission is expected later this year. This type of announcement, detailing clinical trial results and regulatory milestones (like a positive opinion leading to expected approval), is characteristic of an Earnings Release (ER) or a general press release regarding corporate/product news. Since it is an initial announcement of key financial/regulatory progress rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript, management discussion, or a specific shareholder vote result, the most appropriate classification is Earnings Release (ER), as these often include significant operational and regulatory updates alongside financial highlights, or Regulatory Filing (RNS) if it were purely administrative. Given the focus on a major regulatory milestone and clinical data summary, ER is a strong fit for a significant corporate announcement of this nature, although RNS is a possibility. However, ER is often used for major product news releases. Since it is not a full report, and it is a major announcement, ER is selected over RNS, as RNS is the fallback for miscellaneous filings. It is not a Call Transcript (CT) or Investor Presentation (IP). Q3 2021
2021-09-17 English
Galapagos announces planned retirement of CEO
Board/Management Information Classification · 98% confidence The document is a press release announcing the planned retirement of the CEO, Onno van de Stolpe. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The content focuses entirely on leadership transition.
2021-08-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.